No matching results for ''
Tip: Try a valid symbol or a specific company name for relevant results
Canada Markets closed
CMC Crypto 200
CANADA WEEKLY BRIEF
STAY UP TO DATE WITH THE MOST IMPORTANT CANADIAN BUSINESS AND FINANCE NEWS
Sign up for the Canada Weekly Brief and get all you need to know delivered right to your inbox
Repro Med Systems, Inc. (KRMD)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
At close: 4:00PM EDT
177 reactions on $KRMD conversation
Sign in to post a message.
2.00 in next 30 days
I’m in at $5.76. My research is showing that $9.50 is a fair and achievable price.
Good Q1 2020 results. What’s people’s thoughts?
FDA Approves Xembify (immune globulin subcutaneous) for Primary Immunodeficiencies
Barcelona, July 4, 2019.- Grifols, a leading global producer of plasma-derived medicines, announced today that Xembify, its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (FDA). Xembify is used to treat primary immunodeficiencies
RMS has partnered with Grifols to provide the pumps. This is a validation of the RMS strategy of partnering with drug companies as they introduce Sub Q therapies. The revenue stream from this partnership looks to start by the end of the year.
Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) today announced that Dan Goldberger, Executive Chairman, will be presenting at the 29th Annual Oppenheimer Healthcare Conference in New York, NY on Tuesday, March 19th.
OK Repro, I took a long position yesterday.....Make me proud.
Q1 earnings to be released Tuesday after market closes with CC the following day before market opens. Stock seems to be trending up on good volume prior to earnings. Same thing happened last quarter and investors were disappointed. This quarter will be different. The one time expenses of last quarter are behind us. Some fourth quarter sales were delayed until this quarter. Look for 20% YOY top line growth, Bottom line looks like a return to profitability. First quarter with new management team at the wheel. This is the first, very early peek at how they are doing.I am crossing my fingers and expecting better things down the line.
⭐ This is a very Bullish Chart, traders! 💰💵📈
We should all do what GameStop did!!
RMS Medical Products Receives Another Favorable Court Ruling
Download as PDFSeptember 03, 2019
CHESTER, N.Y.--(BUSINESS WIRE)-- Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) (“RMS Medical” or “the Company”) today announced that on August 30, 2019 the United States District Court for the Southern District of New York (Case No. 1:18-cv-05880-LGS) issued a decision granting RMS Medical’s motion for summary judgement of non-infringement against EMED Technologies (“EMED”) U.S. Patent 9,808,576 (“576 Patent”) and dismissed the case with prejudice.
On November 7, 2017, EMED filed this case in the United States District Court for the Eastern District of Texas claiming patent infringement of the ‘576 Patent by the Company’s needle sets and seeking unspecified monetary damages. The case was later transferred to the United States District Court for the Southern District of New York and is one of several pending between RMS Medical and EMED.
Analysts rose rates to strong buy
why there isn't anual report yet??
KRMD to be added to the Russell index as of Friday, the 26th. This means all those ETFs that follow the Russell indices have to include KRMD in their portfolios. Look for increased volume over the next to weeks as buying increases. This usually translates into a 10% increase in share price, just more good news for us longs!!
27.3M$ in cash
RMS Medical Products initiated with a Buy at Craig-Hallum Craig-Hallum analyst Alexander Nowak started RMS Medical Products with a Buy rating and $5.50 price target. With a trend toward in-home infusion, an overabundance of drugs moving to subQ and a company now focused on the pump partnership opportunity, the analyst believes RMS could ultimately become a much larger medical device supplier.
I suspect additional analysts will follow.
Lost more than 1/2 of my investment in krmd.
Willing to get out if my loss would be increased by 1/3.
Why is the stock down again??
There is no justifiable reason for this stock to be trading so high. At $19MM in total revenue TTM, REPR is trading at 7.5x current revenue and would need to grow to ~$50MM in 2-3 years to support today's price. The company has not been able to expand its global business, has not introduced any relevant new products, and continues to lag behind others in their segment. This is definitely a stock to sell now before the price dips.
where is the bottom ?
Prices in Canada rise at fastest pace in more than 18 years
Yahoo Finance Canada
Paintmakers Are Running Out of the Color Blue
Cathie Wood: This one simple tailwind will push the bull market to 2038 — here are 3 stocks to ride it
© 2021 Verizon Media. All rights reserved.
About Our Ads